Nobligan (Tramadol Hydrochloride)

Tramadol Hydrochloride, the active ingredient in Nobligan, is an opioid analgesic presented as an oral tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients when other analgesics are insufficient. It can be used in postoperative, injury‑related, or chronic pain conditions under medical supervision.

GNH USA supplies Nobligan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across global markets.

Tramadol Hydrochloride is used to treat pain conditions by acting on central nervous system pathways that modulate nociception. - Acute postoperative pain: provides relief when non‑opioid analgesics are inadequate. - Moderate to severe chronic musculoskeletal pain: helps manage persistent pain such as osteoarthritis. - Cancer‑related pain (adjunct therapy): used as part of a multimodal regimen for tumor‑associated pain. - Neuropathic pain: may be prescribed for certain nerve‑pain conditions when other agents are unsuitable.

Tramadol Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Dizziness: light‑headedness or loss of balance. - Constipation: reduced bowel movements. - Headache: mild to moderate cranial pain. - Somnolence: increased sleepiness or fatigue. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Seizures: convulsive episodes, especially at high doses. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with serotonergic drugs. - Respiratory depression: slowed breathing, potentially life‑threatening. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of tolerance and withdrawal. - Hypotension: significant drop in blood pressure.

When prescribing Tramadol Hydrochloride, clinicians should consider several safety measures to minimize risks. - Assess pain severity: confirm that opioid therapy is appropriate for the patient's pain level. - Evaluate renal and hepatic function: adjust dosage in patients with impaired organ function. - Monitor for signs of dependence: watch for cravings, increased use, or withdrawal symptoms. - Avoid concomitant MAO inhibitors: discontinue MAO‑inhibitors at least 14 days before starting tramadol. - Use the lowest effective dose: titrate to the minimum dose that provides adequate analgesia. - Store at ambient temperature: keep tablets in the original packaging, protect from moisture and heat.

Tramadol Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: increased chance of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): heightened sedation and respiratory depression. - CYP2D6 inhibitors (e.g., quinidine, fluoxetine): may raise tramadol plasma levels, increasing toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce tramadol effectiveness. - Antihypertensive drugs: additive hypotensive effect, monitor blood pressure. - Anticholinergic agents: may exacerbate dry mouth and constipation. - NSAIDs: combined use may increase risk of gastrointestinal bleeding.